Kenvue Inc. $KVUE Shares Acquired by Clal Insurance Enterprises Holdings Ltd

Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 1,506.8% in the second quarter, Holdings Channel reports. The firm owned 26,142 shares of the company’s stock after acquiring an additional 24,515 shares during the period. Clal Insurance Enterprises Holdings Ltd’s holdings in Kenvue were worth $547,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Evergreen Wealth Solutions LLC grew its stake in Kenvue by 2.6% during the first quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company’s stock worth $402,000 after buying an additional 432 shares during the period. Empirical Finance LLC lifted its holdings in shares of Kenvue by 1.8% during the 2nd quarter. Empirical Finance LLC now owns 28,309 shares of the company’s stock valued at $593,000 after acquiring an additional 491 shares in the last quarter. Everett Harris & Co. CA boosted its position in Kenvue by 1.4% during the 1st quarter. Everett Harris & Co. CA now owns 36,971 shares of the company’s stock worth $887,000 after purchasing an additional 500 shares during the period. Proffitt & Goodson Inc. increased its holdings in Kenvue by 8.2% in the 2nd quarter. Proffitt & Goodson Inc. now owns 6,831 shares of the company’s stock valued at $143,000 after purchasing an additional 517 shares in the last quarter. Finally, UMB Bank n.a. raised its position in Kenvue by 22.3% in the second quarter. UMB Bank n.a. now owns 2,853 shares of the company’s stock valued at $60,000 after purchasing an additional 521 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $16.30 on Wednesday. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The business has a 50 day moving average price of $16.32 and a two-hundred day moving average price of $19.93. The firm has a market cap of $31.22 billion, a PE ratio of 21.73, a price-to-earnings-growth ratio of 2.40 and a beta of 0.71.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be given a $0.2075 dividend. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 5.1%. Kenvue’s payout ratio is presently 110.67%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on KVUE shares. JPMorgan Chase & Co. decreased their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. UBS Group decreased their price target on Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a report on Wednesday, October 8th. Citigroup lowered their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, October 9th. Redburn Partners set a $22.00 price objective on shares of Kenvue in a research note on Friday, September 26th. Finally, Canaccord Genuity Group restated a “hold” rating and issued a $15.00 target price (down from $26.00) on shares of Kenvue in a research note on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus price target of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.